but I’ve got time and with all the incoming catalysts the upside is much greater than the downside at this point.

From my observation with this stock they have a good number of long term and short term catalysts.

Pretty good trap line of potential catalysts.

More catalyst coming which will only keep raising the SP.

$AKBA as an update here akba is now 2 for 2 in positive catalysts.

This is the start of a sustained huge rally as we have addition near term catalysts.

$AKBA several months of positive catalysts lined up.

$AKBA a positive opinion with CHMP is a catalyst that is twofold.

Catalysts on Monday, and investors are showing they believe in MYO. TRENDING

These are all positive catalysts!

$ARDX Come on this stock is meeting every catalyst!!!

Still plenty of positive catalysts in the short and long term

The risk here is GONE, and there are numerous catalysts coming this year.

And I’m loving the upcoming catalysts. ✌️

Near-term FDA catalyst just weeks away, which will likely drive stock to new 52 week highs.

Several catalysts over the next few months make this a great investment to hold.

The advantage that we have is next week there is an Adcom that is going to be a major catalyst to propel this up while the others are lagging.

$ARDX nice looking setup for continuation - big catalyst ADCOM coming mid November - risk 1.3 ISH

The good news is that once our catalysts hit, this will all be water under the bridge ✌🏻

One more catalyst to keep eye on.

Another catalyst could be operating at a profit this year, which should excite the analysts.

2023 should be a good year with increasing revenue, data readouts and other catalyst.

Considering where we are with developments and next steps / catalysts, 2023 could be a grest year here!

Significant catalysts.

but red, as we sit here patiently for our next significant catalyst, whatever that may be ✌🏻 Long and Strong 💪🏻 Always and forever bullish on my KemPharm 😉

$KMPH our two best catalysts in the next few months would be words 1) JPOW .. we are seeing positive xxxxx 2) The Duane… we are seeing relevant royalties and milestones coming in xxxxx

As we proceed through Q4 with some healthy catalysts, continue to increase Azstarys script sales, and approach our Arimoclomol submission in Q1, I believe this chart will continue to look way more impressive. ✌🏻

Script growth, milestones, nda resubmission are all catalysts to move the stock higher.